- Select a blog category
Over the last 15 months some of our Monitor Deloitte colleagues have been working with the Office of Life Sciences to help the UK establish a programme of accelerated access to clinical innovation for NHS patients and a healthy environment for the Life sciences industry. This week’s blog introduces the latest results of our involvement – the publication of a ‘How to Guide’ from early idea development through to large scale adoption.
In our report in 2014, Better care for frail older people, we identified, among many other concerns, the issue of chronic loneliness which evidence suggests is as bad for health as smoking 15 cigarettes a day. Indeed, I had previously written a blog in 2013 on Chronic Loneliness - the next Public Health Challenge. I was therefore delighted when one of our new joiners, offered to write this week’s blog on tackling loneliness in older people, based on her first-hand experience and I hope that if more of us implement some of the suggestions then we can start to reverse this rising trend.
Last May I wrote about the launch of the Dying Matters Awareness Week (DMAW), whose theme, ‘Talk Plan Live’, highlighted the importance of talking about dying and, importantly, of planning ahead.i On Monday evening (9th May), I attended the launch of this year’s campaign, ‘The Big Conversation: Talking about dying won’t make it happen!’ Once again, the aim is to encourage people to talk to their loved ones about dying so that their wishes can be met and important things are not left unsaid.ii Whilst death happens to all of us, most of us still do not feel comfortable talking about dying, death or bereavement. I hope that by sharing my own personal story, this week’s blog might help encourage you to feel more comfortable talking about the only certainty in all our lives.
When I think back on the 16 years I spent in market research and consulting for the life sciences industry, much of my time was spent forecasting. Forecasting informs a multitude of activities and decisions, both strategic and tactical, within the industry and I was lucky enough to be immersed in many of these:
- assessing the market potential of a new product launch
- quantifying commercial opportunity within a new geography
- estimating the size of a therapy area or indication
- evaluating the impact of a new competitor on a market incumbent
- predicting the likely returns of a product at different price points
- gauging the commercial potential of an acquisition or divestment, be it an asset, a portfolio of assets or a company level
- forecasting the size of a salesforce for a new product launch, to name just a few.
April 30th is National Take Back Day in the US. Take back events encourage consumers/patients to return unused medicines that are lying around their homes to pharmacies, so that they can be disposed of properly. This reminded me of a recent experience that troubled me enormously.
We’ve often written blogs about the adoption of innovation and how innovation and technology is helping to support healthcare providers to work differently but it can often feel a little remote to our everyday experiences. This week I’m delighted to share with you a blog written by one of our Monitor Deloitte colleagues who took a sabbatical in late 2015 from her role as a Strategy Consultant in order to support the development of micro-enterprises in rural Nicaragua.
Earlier this week I was discussing our up and coming Healthcare and Life Sciences Essentials course with a new joiner Pavithra Rallapalli, known as Pavi, who recently completed her Post doctoral fellowship at University College London. Her experience was facinating and, not one to miss a chance, I asked Pavi whether she might be interested in writing a Centre blog, and if so what would she want to write about.
This week we’re delighted to feature a ‘my take’ written by our US colleague Harry Greenspun – MD, Director, Center for Health Solutions. We thought it would strike a cord with those fair weather cyclists who are starting to emerge from winter hibernation, but also to those of us interested in learning how the US Med-Tech industry is adapting to new value based payment models.
Some of you reading this blog may already be hooked on the new BBC One drama, The A Word, which shows the reverberation felt across one seemingly perfect family when its youngest member, Joe, is diagnosed with autismi. Others may have seen it advertised and thought the subject matter didn’t resonate or would be too uncomfortable to watch. Certainly that was my husband’s initial reaction but watch it he did and we both found portrayal of this much misunderstood condition very enlightening. Not only does it provide some idea of how wide and varied the condition is, it also highlights that being given a diagnosis is not only life changing for the child, but also for the whole family. As it happens, next week, Saturday 2 April to Friday 8 April, is World Autism Awareness Weekii so I thought I’d use this week’s blog to provide some facts, figure and insights on autism and contribute in a small way to raising awareness about the condition.
The UK, like most other European governments, are facing increasing pressure on their health budgets. One of the reasons for this is the acceleration of medical innovations which are increasing the demand for state-of-the-art treatment. As a result, governments need to get more value for their spending and are considering how best to incentivise “value-based healthcare” (outcomes of health treatment relative to cost).
The Centre for Health Solutions report Better Care for Frail Older People highlighted the challenge of caring for an increasingly frail and ageing population, including the need to improve access to care in all places of care. This week’s blog is a personal take from one of our senior consultants who spent seven years of his career working for a major aged care provider in the UK, where he saw first-hand the pressures that the sector is facing in dealing with an ever-ageing population and increasing numbers of people suffering from dementia. An experience that led him to question whether there will still be a care home sector in 2030?